Inactive Instrument

Oxygen Biotherapeutics, Inc. Share Price Nasdaq

Equities

US69207P2092

Biotechnology & Medical Research

End-of-day quote Nasdaq
- USD - Intraday chart for Oxygen Biotherapeutics, Inc.
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2024 * - Sales 2025 * - Capitalization 6.15M 485M
Net income 2024 * -19M -1.5B Net income 2025 * -18M -1.42B EV / Sales 2024 * -
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * -
P/E ratio 2024 *
-0.38 x
P/E ratio 2025 *
-0.85 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.65%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 50 13/07/21
Director of Finance/CFO 69 01-10
Chief Tech/Sci/R&D Officer 74 14/01/21
Members of the board TitleAgeSince
Chairman 65 03/04/14
Director/Board Member 67 24/02/21
Director/Board Member 72 24/02/21
More insiders
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 (IV), TNX-102 (subcutaneous) and TNX-103 (oral) levosimendan. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW